| Document |
Document Title |
|
JP2022507879A |
In the present invention, the formula (Ia) (in the formula, the XY group is -NHSO2-Or-SO2NH-is; R1Is H or alkyl; R2Is selected from COOH and tetrazolyl groups; R3Is selected from H, Cl and alkyl; R4Is selected from H, Cl and F; R5H, alky...
|
|
JP6997455B2 |
Free-standing non-fouling polymers and polymeric compositions, monomers and macromonomers for making the polymers and polymeric compositions, objects made from the polymers and polymeric compositions, and methods for making and using the...
|
|
JP6995695B2 |
The present invention is a method for purifying an NCA, including the steps of: a) dissolving an NCA contaminated with impurities into a solvent which is a good solvent and is not a chlorinated solvent followed by stirring to precipitate...
|
|
JP2022504697A |
In the present specification, a compound that is a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, a method for making such a compound, a pharmaceutical composition and a drug containing such a compound, and a disease or disease ...
|
|
JPWO2020145250A1 |
To provide a compound having a 15-PGDH inhibitory action. A compound represented by the general formula (1) or a pharmacologically acceptable salt thereof. [Selection diagram] None
|
|
JP2021014406A |
To provide a compound that is highly water-soluble and has a vasopressin V2 receptor antagonistic action, which is particularly suitable for parenteral injections, and to provide a pharmaceutical containing said compound.Provided are a c...
|
|
JP6820254B2 |
and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a...
|
|
JP6786527B2 |
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
|
|
JP2020114814A |
To provide a novel process for making PI3K inhibitor compound GDC-0032.There is provided a method for preparing PI3K inhibitor GDC-0032 having a structure described above and stereoisomers, geometrical isomers, tautomers and pharmaceutic...
|
|
JP2020045306A |
To provide compounds or pharmacologically acceptable salts thereof that have excellent EP300 and/or CREBBP histone acetyltransferase inhibitory activity.The invention provides compounds represented by the formula (1) in the figure or pha...
|
|
JP6668362B2 |
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:where R, L, X1, X2, X3, X4, Y1, Y2, Y3,...
|
|
JP6641367B2 |
The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addit...
|
|
JP6590927B2 |
The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (l),which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders relat...
|
|
JP6582056B2 |
wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and A1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containin...
|
|
JP6567393B2 |
The invention relates to compounds of formula wherein R is hydrogen or lower alkyl; R 1 is -(CH 2 ) n -(O) o -heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydrox...
|
|
JP2019089762A |
To provide processes for the preparation of PI3K inhibitor, GDC-0032.The present invention provides GDC-0032 shown below, and intermediates useful for the preparation of the same.SELECTED DRAWING: None
|
|
JP2019513773A |
The present invention presents a novel herbicidal activity according to the general formula (I) of a cyclized 3-phenyltetramic acid derivative or a pesticide-acceptable salt thereof, and these compounds for controlling weeds and grass we...
|
|
JP6470969B2 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...
|
|
JP6469711B2 |
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxam
ide compounds (including pharmaceutically acceptable salts thereof),that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their util...
|
|
JP2018203771A |
To provide: compounds that are sodium channel inhibitors; and their compounds in the treatment of various disease states, including cardiovascular diseases and diabetes.This invention relates to a compound of formula I, wherein -Y-Z- is ...
|
|
JP2018199677A |
To provide a therapeutic compound and composition.There is provided an arylsulfonamide diaryl urea derivative compound, which is an inhibitor of mutated isocitrate dehydrogenase enzyme 1/2 (IDH1/2) and is useful for a treatment of cancer...
|
|
JP6442005B2 |
Processes are described for the preparation of PI3K inhibitor, GDC-0032, Formula I, having the structure:and intermediates useful for the preparation of I.
|
|
JP2018531919A |
The present disclosure partially provides compounds having allosteric effector properties against hepatitis B virus Cp. Also provided herein is a method of treating a viral infection, eg, hepatitis B, which comprises the step of administ...
|
|
JP2018150298A |
To provide processes for the preparation of PI3K inhibitor, GDC-0032.The present invention provides a method including making a compound of III react with ethyl 2-methyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-
1H-pyrazol-1-yl...
|
|
JP6385352B2 |
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a su...
|
|
JP6363120B2 |
Processes are described for the preparation of PI3K inhibitor, GDC-0032, Formula I, having the structure:and intermediates useful for the preparation of I.
|
|
JP6321045B2 |
Disclosed are compounds having the formula (I)wherein X, Y, Z, Z, Z, Z, R, R, m, A, L, and B are as defined herein, and methods of making and using the same.
|
|
JP2018510159A |
Provided herein are compounds of formula (I) useful for the treatment of HBV infection in subjects in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing or preventing HBV infection in subjects. [Che...
|
|
JP6281952B2 |
The present invention provides a novel compound having an antiviral activity, in particular, an HIV replication inhibiting activity, as well as a pharmaceutical composition, in particular, an anti-HIV agent. wherein ring A is substituted...
|
|
JP6273250B2 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.
|
|
JP6266509B2 |
|
|
JP2017532345A |
The present invention discloses a novel polyolefin polymerization catalyst and its production. Specifically, the present invention discloses a novel catalyst system containing a complex of iron, cobalt, nickel, palladium, and platinum. U...
|
|
JP6224154B2 |
Disclosed is a method for preparing a poly(ethersulfonimide or ethersulfonamide) copolymer using cyclic oligomers, and more particularly, to a method for preparing a poly(ethersulfonimide or ethersulfonamide) copolymer by preparing a cyc...
|
|
JP2017523972A |
The present invention relates to a novel FLT3 receptor antagonist of the general formula (1). The compounds are useful in the treatment or prevention of pain disorders, cancers, and autoimmune diseases. [Chemical 1] [Selection diagram] None
|
|
JP2017512766A |
The genus of aryl sulfonamide derivatives of aminocycloalkanols is disclosed. This compound belongs to the following genus (I). This compound induces the translocation of the FOXO1 transcription factor to the nucleus by regulating PP2A, ...
|
|
JP2017088630A |
To provide compounds that are sodium channel inhibitors, and the use of the compounds in the treatment of various disease states, including cardiovascular diseases and diabetes.The present disclosure relates to compounds that are sodium ...
|
|
JP2017081931A |
To provide antibacterial agents which can prevent infections cause by gram-negative bacteria, other compounds for use in the preparation of medicines and combinations of such compounds.The present invention provides a compound represente...
|
|
JP6117430B2 |
The present invention relates to novel urea derivatives and, more particularly, to novel urea derivatives with histone deacetylase (HDAC) inhibitory activity, isomers thereof, pharmaceutically acceptable salts thereof, their use for the ...
|
|
JP2017510553A |
The present disclosure provides a method for the preparation of compounds of the formula, which are selective delayed sodium current inhibitors. The disclosure also provides compounds that are synthetic intermediates. The present disclos...
|
|
JP6109575B2 |
The invention relates to compounds of formula wherein R is hydrogen or lower alkyl; R 1 is -(CH 2 ) n -(O) o -heterocycloalkyl or -C(O)-heterocycloalkyl, wherein the heterocycloalkyl group is optionally substituted by lower alkyl, hydrox...
|
|
JPWO2015056782A1 |
An object of the present invention is to provide a novel compound having ACC2 inhibitory activity. In addition, a pharmaceutical composition containing the above compound is provided. Equation (I):(In the formula, R1Is a substituted or u...
|
|
JP2017504626A |
Provided herein are compounds useful for the treatment of HBV infection in subjects in need thereof, their pharmaceutical compositions and methods of inhibiting, suppressing or preventing HBV infection in subjects.
|
|
JP2017019826A |
To provide a method for conducting a target therapy in a subject having a frontotemporal lobar degeneration using FTLD (frontotemporal lobar degeneration) target drug.There is provided a target therapy of FTLD exhibiting high brain perme...
|
|
JP6068505B2 |
The invention relates to a compound of formula (I) wherein A, B, D and R1 to R6 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
JP6054900B2 |
|
|
JP2016183191A |
To provide anthraquinone analogs and methods of making and using thereof.Rhein analogs that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or ...
|
|
JP2016529238A |
The present invention relates to a compound of formula (I). [Chemical 1]Provided are a method for producing a compound of the present invention and a therapeutic use thereof. The present invention further provides a combination of a phar...
|
|
JP2016521259A |
The present invention comprises the substitutions N-biphenyl-3-acetylamino-benzamide and N- [3- (acetylamino) phenyl] -biphenyl-carboxamide of the general formula (I) described and defined herein, said compounds. Methods of preparation, ...
|
|
JP2016513112A |
Compounds are provided that include one or more subclass modulators of the vasopressin receptor, such as the positive allosteric modulators, piperazine, piperidine, spiro-furanopiperidine, and analogs thereof. The compound can be a selec...
|
|
JP5889407B2 |
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes.
|
